Bold Goals for Biotechnology:
Promoting continued innovation and progress in the bioeconomy

Biotechnology addresses some of society’s greatest challenges. Implementing the administration’s Bold Goals would promote continued innovation and incentivize even more progress in the bioeconomy.

On September 12, 2022, President Biden signed an Executive Order (EO) that would advance “biotechnology and biomanufacturing Innovation for a sustainable, safe, and secure American bioeconomy.”

BIO wholeheartedly supports the Biden administration’s EO and its related “Bold Goals for U.S. Biotechnology and Biomanufacturing.” We urge action to operationalize those goals.

The Biden administration outlined an agenda to advance biotechnology and biomanufacturing in five sectors:

- **Climate**: In 20 years, demonstrate and deploy routes to convert bio-based feedstocks into recyclable-by-design polymers that can displace more than 90% of today’s plastics and other commercial polymers at scale.

- **Food and Agriculture**: By 2030, reduce methane emissions from agriculture to support the U.S. goal of reducing greenhouse gas emissions by 50% and the global goal of reducing methane emissions by 30%.

- **Supply Chain**: In 20 years, produce at least 30% of the U.S. chemical demand via sustainable and cost-effective biomanufacturing pathways.

- **Health**: In 20 years, increase the manufacturing scale of cell-based therapies to expand access, decrease health inequities, and decrease the manufacturing cost of cell-based therapies 10-fold.

- **Cross-Cutting Advances**: In five years, sequence the genomes of 1 million microbial species and understand the function of at least 80% of the newly discovered genes.
Biotechnology can address global health crises, environmental stewardship, and food security in a growing world.

Achieving these ambitious goals requires:

1. Leading with science and U.S. innovation,
2. Adopting more sustainable technologies and practices, and
3. Streamlining and expediting regulatory pathways for breakthrough technology.

However, real, meaningful action is still needed to reduce ambiguities, inefficiencies, and uncertainties as it pertains to the U.S. Coordinated Framework for the Regulation of Biotechnology.

The administration must prioritize clarity and efficiency in regulating biotechnology by:

- Acting on and advancing the policy and regulatory objectives outlined in Executive Order 14081 and its resulting “Bold Goals for U.S. Biotechnology and Biomanufacturing” report.
- Facilitating interagency coordination between the U.S. Department of Agriculture, the U.S. Environmental Protection Agency, and the U.S. Food and Drug Administration.
- Encouraging government officials to catalyze public-private partnerships to further accelerate the gains made by biotechnology.

By proactively advancing biotechnology, we can take bold action to tackle its highest priority issues. **BIO and our member companies are committed to working with the Office of Science and Technology Policy and the administration to deliver pioneering technology breakthroughs that improve the health, environment, and prosperity of our nation and the world.**